Scripps Clinic, La Jolla, CA, USA.
Catheter Cardiovasc Interv. 2010 Jun 1;75(7):1076-83. doi: 10.1002/ccd.22414.
Contrast-induced nephropathy (CIN) after coronary angiography or intervention is associated with substantial morbidity. The data supporting various prophylactic measures and adjunctive therapies to prevent this complication are conflicting. However, contrast volume is clearly related to CIN after percutaneous coronary intervention (PCI), and the risk of CIN has been shown to be directly related to contrast dose. Therefore, minimizing contrast exposure is a primary method to reduce the risk of CIN, especially in at-risk patients. We report a novel technique designed to deliver ultra-low (<15 cm(3)) volume contrast to patients with chronic kidney disease undergoing coronary angiography and PCI.
冠状动脉造影或介入术后对比剂肾病（CIN）与较大的发病率相关。支持各种预防措施和辅助治疗以预防该并发症的数据相互矛盾。然而，经皮冠状动脉介入治疗（PCI）后对比剂用量显然与 CIN 相关，CIN 的风险已被证实与对比剂剂量直接相关。因此，尽量减少对比剂暴露是降低 CIN 风险的主要方法，尤其是在高危患者中。我们报告了一种新的技术，旨在为接受冠状动脉造影和 PCI 的慢性肾脏病患者提供超低（<15cm3）量的对比剂。
